Current Heart Failure Reports

, Volume 8, Issue 2, pp 99–105 | Cite as

Renal Biomarkers of Kidney Injury in Cardiorenal Syndrome

Article

Abstract

The cardiorenal syndromes comprise a group of disorders in which impairment of either the heart or the kidney results in injury to the other. Although the pathophysiology is not yet well understood, the clinical consequences are increasingly recognized. In congestive heart failure, the development of worsening renal function is associated with increased hospitalizations and death. Urinary biomarkers offer a rapid and noninvasive method for detecting kidney injury. The role of urinary biomarkers such as neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, N-acetyl-β-D-glucosaminidase, interleukin-18, and cystatin C are being investigated to provide diagnostic, prognostic, and, eventually, therapeutic information. This article reviews the utility of urinary biomarkers in congestive heart failure and explores directions for future research.

Keywords

Cardiorenal syndrome Heart failure Acute kidney injury Epidemiology NGAL Cystatin C Albuminuria N-Acetyl-β-D-Glucosaminidase Kidney injury molecule-1 Neutrophil gelatinase-associated lipocalin 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–214.PubMedCrossRefGoogle Scholar
  2. 2.
    • Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703–11. This is a detailed description of the five types of cardiorenal syndromes. PubMedGoogle Scholar
  3. 3.
    •• Sarraf M, Masoumi A, Schrier R. Cardiorenal syndrome in acute decompensated heart failure. CJASN 2009;4:2013–26. This is a thorough, in-depth review of the proposed pathophysiology involved in cardiorenal syndromes. PubMedGoogle Scholar
  4. 4.
    •• Stenvinkel P, Carrero JJ, Axelson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? CJASN 2008, 3: 505–21. This is an excellent discussion of systemic effects in chronic kidney disease and their contribution to morbidity and mortality. PubMedGoogle Scholar
  5. 5.
    Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Failure. 2002;8:136–41.CrossRefGoogle Scholar
  6. 6.
    Damman K, Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Damman K, Voors AA, Hillege HL, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J of Heart Fail 2010;1–9.Google Scholar
  8. 8.
    Nohria A, Hasselblad V, Stebbens A, et al. Cardiorenal interactions insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138:849–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006;27:1216–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Damman K, Navis G, Smilde TDJ, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J of Heart Fail. 2007;9:872–8.CrossRefGoogle Scholar
  13. 13.
    Perez AV, Otawa K, Zimmermann AV, et al. The impact of impaired renal function on mortality in patients with acutely decompensated chronic heart failure. Eur J of Heart Failure. 2010;12:122–8.CrossRefGoogle Scholar
  14. 14.
    Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure. J Am Coll Cardiol. 2008;51:300–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Mullens W, Abrahams Z, Francis GS, et al. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J of Card Fail. 2008;14:508–14.CrossRefGoogle Scholar
  16. 16.
    Constanza MR, Saltzberg MT, Jessup M, et al. Ultrafiltration is associated with fewer hospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD. J of Card Fail. 2010;16:277–84.CrossRefGoogle Scholar
  17. 17.
    Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. JACC. 2004;43:61–7.PubMedGoogle Scholar
  18. 18.
    Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalized for acute heart failure: clinical implications and prognostic significance. Eur J of Heart Fail. 2008;10:188–95.CrossRefGoogle Scholar
  19. 19.
    Smith GL, Lichtman JH, Bracken MB, et al. Renal Impairment and outcomes in heart failure. J Am Coll Cardiol. 2006;47:1987–96.PubMedCrossRefGoogle Scholar
  20. 20.
    Damman K, Jaarsma T, Voors AA, et al. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J of Heart Fail. 2009;11:847–54.CrossRefGoogle Scholar
  21. 21.
    Cruz DM, Goh CY, Haase-Fielitz A, et al. Early biomarkers of renal injury. Congest Heart Fail. 2010;16:S25–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Lainscak M, Anker MS, Haehling S, et al. Biomarkers for chronic heart failure. Herz. 2009;34:589–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Hillege HL, Janssen WMT, Bak AAA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519–26.PubMedCrossRefGoogle Scholar
  24. 24.
    Bonnet F, Marre M, Halimi JM, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J of Hypertension. 2006;24:1157–63.CrossRefGoogle Scholar
  25. 25.
    Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.PubMedCrossRefGoogle Scholar
  26. 26.
    Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Reffelmann T, Dorr M, Volzke H, et al. Urinary albumin excretion, even within the normal range, predicts an increase in left ventricular mass over the follow 5 years. Kidney Int. 2010;77:1115–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Ingelsson E, Sundstrom J, Lind L, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J. 2007;28:1739–45.PubMedCrossRefGoogle Scholar
  30. 30.
    • Jackson CE, Soloman SD, Gerstein HC, et al. Albuminura in chronic heart failure: prevalence and prognostic importance. Lancet 2009;374:543–50. This is an interesting analysis of the morbidity and mortality of albuminuria from the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) trial. PubMedCrossRefGoogle Scholar
  31. 31.
    • Masson S, Latini VM, Moretti L, et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure. Circulation Heart Failure 2010;3:65–72. This is a second interesting analysis of the morbidity and mortality of albuminuria from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico [Italian group for the study of the survival of myocardial infarction]) trial. PubMedCrossRefGoogle Scholar
  32. 32.
    Anand IS, Bishu K, Rector TS, et al. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation. 2009;120:1577–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Bolignano D, Coppolino G, Romeo A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrol Dial Transplant. 2009;24:3398–403.PubMedCrossRefGoogle Scholar
  34. 34.
    Malysko J, Tesar V, Macdougall IC. Neutrophil gelatinase-associated lipocalin and hepcidin: what do they have in common and is there a potential interaction? Kidney Blood Press Res. 2010;33:157–65.CrossRefGoogle Scholar
  35. 35.
    Friedl A, Stoesz SP, Buckley P, et al. Neutrophil gelatinase associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999;31:433–41.PubMedCrossRefGoogle Scholar
  36. 36.
    Meijer E, Boertien WE, Nauta FL, et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kid Dis. 2010;56:883–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Ding H, He Y, Li K, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol. 2007;123:227–34.PubMedCrossRefGoogle Scholar
  38. 38.
    Paragas N, Nickolas TL, Wyatt C, et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. JASN. 2009;20:1687–92.PubMedGoogle Scholar
  39. 39.
    Yilmaz A, Sevketoglu E, Gedikbasi A, et al. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol. 2009;24:2387–92.PubMedCrossRefGoogle Scholar
  40. 40.
    Bagshaw SM, Bennett M, Haase M, et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Intensive Care Med. 2010;36:452–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. CJASN. 2008;3:665–74.PubMedGoogle Scholar
  42. 42.
    Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Tuladhar SM, Puntmann VO, Soni M, et al. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol. 2009;53:261–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Han W, Wagener G, Zhu Y, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. CJASN. 2009;4:873–82.PubMedGoogle Scholar
  45. 45.
    Xin C, Yulong X, Yu C, et al. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Ren Fail. 2008;30:904–13.PubMedCrossRefGoogle Scholar
  46. 46.
    Heise D, Rentsch K, Braeuer A, et al. Comparison of urinary neutrophil glucosaminidase-associated lipocalin, cystatin-C, and α1-microglobulin for early detection of acute renal injury after cardiac surgery. European J of Cardio-Thoracic Surgery 2010; in press.Google Scholar
  47. 47.
    Damman K, Veldhuisen DJ, Navis G, et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. European J of Heart Failure. 2008;10:997–1000.CrossRefGoogle Scholar
  48. 48.
    Damman K, Veldhuisen DJ, Navis G, et al. Tubular damage is chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010;96:1297–302.PubMedCrossRefGoogle Scholar
  49. 49.
    Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J of Cardiac Failure. 2010;16:49–54.CrossRefGoogle Scholar
  50. 50.
    Bonventre JV, Yang L. Kidney injury molecule-1. Curr Opin Crit Care. 2010;16:1–6.CrossRefGoogle Scholar
  51. 51.
    Han WK, Alinani A, Wu CL, et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. JASN. 2005;16:1126–34.PubMedGoogle Scholar
  52. 52.
    Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-β-(D)-glucosaminidase activity and kidney injury molecule-1 are associated with adverse outcomes in acute renal failure. JASN. 2007;18:904–12.PubMedGoogle Scholar
  53. 53.
    Parikh CR, Jani A, Melnikov VY, et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43:405–11.PubMedCrossRefGoogle Scholar
  54. 54.
    Parikh CR, Mishra J, Theissen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70:199–203.PubMedCrossRefGoogle Scholar
  55. 55.
    Haase M, Bellomo R, Story D, et al. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit Care. 2008;12:1–8.CrossRefGoogle Scholar
  56. 56.
    Parikh CR, Abraham E, Ancukiewicz M, et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. JASN. 2005;16:3046–52.PubMedGoogle Scholar
  57. 57.
    Fricker M, Wiesli P, Brandle M, et al. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63:1944–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Koyner JL, Bennett MR, Worcester EM, et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008;74:1059–69.PubMedCrossRefGoogle Scholar
  59. 59.
    Nejat M, Pickering JW, Walker RJ, et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care. 2010;14:1–1.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA)  2011

Authors and Affiliations

  1. 1.Division of Renal Diseases and HypertensionUniversity of MinnesotaMinneapolisUSA
  2. 2.Minneapolis VA Health Care SystemMinneapolisUSA

Personalised recommendations